Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Pulmonary Fibrosis-Pipeline Review, H1 2015

Pulmonary Fibrosis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Pulmonary Fibrosis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Pulmonary Fibrosis-Pipeline Review, H1 2015', provides an overview of the Pulmonary Fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Pulmonary Fibrosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Pulmonary Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Pulmonary Fibrosis Overview 10

Therapeutics Development 11

Pipeline Products for Pulmonary Fibrosis-Overview 11

Pipeline Products for Pulmonary Fibrosis-Comparative Analysis 12

Pulmonary Fibrosis-Therapeutics under Development by Companies 13

Pulmonary Fibrosis-Therapeutics under Investigation by Universities/Institutes 19

Pulmonary Fibrosis-Pipeline Products Glance 20

Late Stage Products 20

Clinical Stage Products 21

Early Stage Products 22

Unknown Stage Products 23

Pulmonary Fibrosis-Products under Development by Companies 24

Pulmonary Fibrosis-Products under Investigation by Universities/Institutes 30

Pulmonary Fibrosis-Companies Involved in Therapeutics Development 31

AdAlta Pty Ltd. 31

Aeolus Pharmaceuticals, Inc. 32

AnaptysBio, Inc. 33

Angion Biomedica Corp. 34

Aquinox Pharmaceuticals Inc. 35

Auspex Pharmaceuticals, Inc. 36

Biogen Idec Inc. 37

BiOrion Technologies B.V. 38

Boehringer Ingelheim GmbH 39

Bristol-Myers Squibb Company 40

Carolus Therapeutics, Inc. 41

Celgene Corporation 42

Chong Kun Dang Pharmaceutical Corp. 43

Compugen Ltd. 44

Corridor Pharmaceuticals Inc. 45

Digna Biotech, S.L. 46

Eli Lilly and Company 47

F. Hoffmann-La Roche Ltd. 48

FibroGen, Inc. 49

Five Prime Therapeutics, Inc. 50

Galectin Therapeutics, Inc. 51

GenKyoTex S.A. 52

Gilead Sciences, Inc. 53

GlaxoSmithKline plc 54

HanAll Biopharma Co., Ltd. 55

Histocell S.L. 56

iBio, Inc. 57

IMMD Inc. 58

ImmuneWorks, LLC 59

IntelGenx Corp. 60

InterMune, Inc. 61

Inventiva SAS 62

Kasiak Research Pvt. Ltd. 63

Kyorin Pharmaceutical Co., Ltd. 64

Lanthio Pharma B.V. 65

Lpath, Inc. 66

LTT Bio-Pharma Co., Ltd. 67

MedImmune, LLC 68

Mesoblast Limited 69

miRagen Therapeutics, Inc. 70

Moerae Matrix, Inc. 71

MSM Protein Technologies, Inc. 72

NicOx S.A. 73

Pacific Therapeutics Ltd. 74

Pharmaxis Limited 75

Pluristem Therapeutics Inc. 76

Progenra, Inc. 77

Promedior, Inc. 78

ProMetic Life Sciences Inc. 79

Pulmatrix, Inc. 80

RestorGenex Corporation 81

Rhizen Pharmaceuticals SA 82

Sanofi 83

Therametrics holding AG 84

Vectura Group plc 85

Pulmonary Fibrosis-Therapeutics Assessment 86

Assessment by Monotherapy Products 86

Assessment by Combination Products 87

Assessment by Target 88

Assessment by Mechanism of Action 92

Assessment by Route of Administration 95

Assessment by Molecule Type 97

Drug Profiles 99

(pentoxifylline + acetylcysteine)-Drug Profile 99

ABC-294640-Drug Profile 100

AEOL-10150-Drug Profile 102

AM-0010-Drug Profile 105

ANG-3070-Drug Profile 106

ANG-3298-Drug Profile 107

Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis-Drug Profile 108

AQX-1125-Drug Profile 109

BB-3-Drug Profile 111

BMS-986020-Drug Profile 113

BOT-191-Drug Profile 114

C-301-Drug Profile 115

CC-539-Drug Profile 116

CC-90001-Drug Profile 117

CG-1011-Drug Profile 118

CGEN-25009-Drug Profile 119

CKD-942-Drug Profile 120

CT-140-Drug Profile 121

CT-2009-Drug Profile 122

DB-02901-Drug Profile 123

disitertide-Drug Profile 124

Drug for Idiopathic Pulmonary Fibrosis-Drug Profile 126

Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis-Drug Profile 127

FG-3019-Drug Profile 128

FPA-008-Drug Profile 130

GKT-137831-Drug Profile 131

GR-MD-02-Drug Profile 132

HC-016-Drug Profile 134

HL-156FIB-Drug Profile 135

HR-017-Drug Profile 136

IBIOCFB-03-Drug Profile 137

ICG-001-Drug Profile 138

IMD-1041-Drug Profile 139

INT-0024-Drug Profile 140

interferon gamma-1b-Drug Profile 141

ITMN-10534-Drug Profile 142

ITMN-14440-Drug Profile 143

ITMN-30162-Drug Profile 144

IVA-337-Drug Profile 145

IW-001-Drug Profile 146

KBP-7018-Drug Profile 147

lebrikizumab-Drug Profile 148

LP2-Drug Profile 150

Lpathomab-Drug Profile 151

LT-0011-Drug Profile 152

LY-2109761-Drug Profile 153

MGN-4220-Drug Profile 154

MMI-0100-Drug Profile 155

Monoclonal Antibody for Idiopathic Pulmonary Fibrosis-Drug Profile 156

MSM-735-Drug Profile 157

MSX-122-Drug Profile 158

NAS-911-Drug Profile 160

NCX-466-Drug Profile 161

nintedanib-Drug Profile 162

Oligonucleotides for Respiratory and Oncology-Drug Profile 166

omipalisib-Drug Profile 167

P-007-Drug Profile 168

P-17-Drug Profile 169

P-529-Drug Profile 171

PBF-1250-Drug Profile 173

PBI-4050-Drug Profile 174

phytate sodium-Drug Profile 175

pirfenidone-Drug Profile 176

PRI-724-Drug Profile 177

PRM-151-Drug Profile 179

PUR-1500-Drug Profile 181

PXS-25-Drug Profile 182

PXS-4820-Drug Profile 183

PXS-5033-A-Drug Profile 184

PXS-64-Drug Profile 185

Recombinant Human Follistatin-Drug Profile 186

Refacell-IPF-Drug Profile 187

RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis-Drug Profile 188

RP-6503-Drug Profile 189

SAR-156597-Drug Profile 190

SD-560-Drug Profile 191

simtuzumab-Drug Profile 192

Small Molecule 1 for Chronic Respiratory Diseases-Drug Profile 194

Small Molecule 2 for Chronic Respiratory Diseases-Drug Profile 195

Small Molecule to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis-Drug Profile 196

Small Molecule to Inhibit NOX 1 and 4-Drug Profile 197

Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis-Drug Profile 198

Small Molecules to Inhibit LOXL2 for Oncology and Fibrosis-Drug Profile 199

Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis-Drug Profile 200

SPL-334-Drug Profile 201

Stem Cell Therapy for Asthma and Pulmonary Fibrosis-Drug Profile 202

Stem Cell Therapy for Idiopathic Lung Fibrosis-Drug Profile 203

Stem Cell Therapy for Pulmonary Fibrosis-Drug Profile 204

STX-100-Drug Profile 205

Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology-Drug Profile 206

Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury-Drug Profile 208

TD-139-Drug Profile 209

tipelukast-Drug Profile 210

tralokinumab-Drug Profile 212

vismodegib-Drug Profile 214

Pulmonary Fibrosis-Recent Pipeline Updates 217

Pulmonary Fibrosis-Dormant Projects 265

Pulmonary Fibrosis-Discontinued Products 269

Pulmonary Fibrosis-Product Development Milestones 270

Featured News & Press Releases 270

Appendix 280

Methodology 280

Coverage 280

Secondary Research 280

Primary Research 280

Expert Panel Validation 280

Contact Us 281

Disclaimer 281

List of Tables

Number of Products under Development for Pulmonary Fibrosis, H1 2015 18

Number of Products under Development for Pulmonary Fibrosis-Comparative Analysis, H1 2015 19

Number of Products under Development by Companies, H1 2015 21

Number of Products under Development by Companies, H1 2015 (Contd..1) 22

Number of Products under Development by Companies, H1 2015 (Contd..2) 23

Number of Products under Development by Companies, H1 2015 (Contd..3) 24

Number of Products under Development by Companies, H1 2015 (Contd..4) 25

Number of Products under Investigation by Universities/Institutes, H1 2015 26

Comparative Analysis by Late Stage Development, H1 2015 27

Comparative Analysis by Clinical Stage Development, H1 2015 28

Comparative Analysis by Early Stage Development, H1 2015 29

Comparative Analysis by Unknown Stage Development, H1 2015 30

Products under Development by Companies, H1 2015 31

Products under Development by Companies, H1 2015 (Contd..1) 32

Products under Development by Companies, H1 2015 (Contd..2) 33

Products under Development by Companies, H1 2015 (Contd..3) 34

Products under Development by Companies, H1 2015 (Contd..4) 35

Products under Development by Companies, H1 2015 (Contd..5) 36

Products under Investigation by Universities/Institutes, H1 2015 37

Pulmonary Fibrosis-Pipeline by AdAlta Pty Ltd., H1 2015 38

Pulmonary Fibrosis-Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 39

Pulmonary Fibrosis-Pipeline by AnaptysBio, Inc., H1 2015 40

Pulmonary Fibrosis-Pipeline by Angion Biomedica Corp., H1 2015 41

Pulmonary Fibrosis-Pipeline by Aquinox Pharmaceuticals Inc., H1 2015 42

Pulmonary Fibrosis-Pipeline by Auspex Pharmaceuticals, Inc., H1 2015 43

Pulmonary Fibrosis-Pipeline by Biogen Idec Inc., H1 2015 44

Pulmonary Fibrosis-Pipeline by BiOrion Technologies B.V., H1 2015 45

Pulmonary Fibrosis-Pipeline by Boehringer Ingelheim GmbH, H1 2015 46

Pulmonary Fibrosis-Pipeline by Bristol-Myers Squibb Company, H1 2015 47

Pulmonary Fibrosis-Pipeline by Carolus Therapeutics, Inc., H1 2015 48

Pulmonary Fibrosis-Pipeline by Celgene Corporation, H1 2015 49

Pulmonary Fibrosis-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 50

Pulmonary Fibrosis-Pipeline by Compugen Ltd., H1 2015 51

Pulmonary Fibrosis-Pipeline by Corridor Pharmaceuticals Inc., H1 2015 52

Pulmonary Fibrosis-Pipeline by Digna Biotech, S.L., H1 2015 53

Pulmonary Fibrosis-Pipeline by Eli Lilly and Company, H1 2015 54

Pulmonary Fibrosis-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 55

Pulmonary Fibrosis-Pipeline by FibroGen, Inc., H1 2015 56

Pulmonary Fibrosis-Pipeline by Five Prime Therapeutics, Inc., H1 2015 57

Pulmonary Fibrosis-Pipeline by Galectin Therapeutics, Inc., H1 2015 58

Pulmonary Fibrosis-Pipeline by GenKyoTex S.A., H1 2015 59

Pulmonary Fibrosis-Pipeline by Gilead Sciences, Inc., H1 2015 60

Pulmonary Fibrosis-Pipeline by GlaxoSmithKline plc, H1 2015 61

Pulmonary Fibrosis-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 62

Pulmonary Fibrosis-Pipeline by Histocell S.L., H1 2015 63

Pulmonary Fibrosis-Pipeline by iBio, Inc., H1 2015 64

Pulmonary Fibrosis-Pipeline by IMMD Inc., H1 2015 65

Pulmonary Fibrosis-Pipeline by ImmuneWorks, LLC, H1 2015 66

Pulmonary Fibrosis-Pipeline by IntelGenx Corp., H1 2015 67

Pulmonary Fibrosis-Pipeline by InterMune, Inc., H1 2015 68

Pulmonary Fibrosis-Pipeline by Inventiva SAS, H1 2015 69

Pulmonary Fibrosis-Pipeline by Kasiak Research Pvt. Ltd., H1 2015 70

Pulmonary Fibrosis-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 71

Pulmonary Fibrosis-Pipeline by Lanthio Pharma B.V., H1 2015 72

Pulmonary Fibrosis-Pipeline by Lpath, Inc., H1 2015 73

Pulmonary Fibrosis-Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 74

Pulmonary Fibrosis-Pipeline by MedImmune, LLC, H1 2015 75

Pulmonary Fibrosis-Pipeline by Mesoblast Limited, H1 2015 76

Pulmonary Fibrosis-Pipeline by miRagen Therapeutics, Inc., H1 2015 77

Pulmonary Fibrosis-Pipeline by Moerae Matrix, Inc., H1 2015 78

Pulmonary Fibrosis-Pipeline by MSM Protein Technologies, Inc., H1 2015 79

Pulmonary Fibrosis-Pipeline by NicOx S.A., H1 2015 80

Pulmonary Fibrosis-Pipeline by Pacific Therapeutics Ltd., H1 2015 81

Pulmonary Fibrosis-Pipeline by Pharmaxis Limited, H1 2015 82

Pulmonary Fibrosis-Pipeline by Pluristem Therapeutics Inc., H1 2015 83

Pulmonary Fibrosis-Pipeline by Progenra, Inc., H1 2015 84

Pulmonary Fibrosis-Pipeline by Promedior, Inc., H1 2015 85

Pulmonary Fibrosis-Pipeline by ProMetic Life Sciences Inc., H1 2015 86

Pulmonary Fibrosis-Pipeline by Pulmatrix, Inc., H1 2015 87

Pulmonary Fibrosis-Pipeline by RestorGenex Corporation, H1 2015 88

Pulmonary Fibrosis-Pipeline by Rhizen Pharmaceuticals SA, H1 2015 89

Pulmonary Fibrosis-Pipeline by Sanofi, H1 2015 90

Pulmonary Fibrosis-Pipeline by Therametrics holding AG, H1 2015 91

Pulmonary Fibrosis-Pipeline by Vectura Group plc, H1 2015 92

Assessment by Monotherapy Products, H1 2015 93

Assessment by Combination Products, H1 2015 94

Number of Products by Stage and Target, H1 2015 96

Number of Products by Stage and Mechanism of Action, H1 2015 100

Number of Products by Stage and Route of Administration, H1 2015 103

Number of Products by Stage and Molecule Type, H1 2015 105

Pulmonary Fibrosis Therapeutics-Recent Pipeline Updates, H1 2015 224

Pulmonary Fibrosis-Dormant Projects, H1 2015 272

Pulmonary Fibrosis-Dormant Projects (Contd..1), H1 2015 273

Pulmonary Fibrosis-Dormant Projects (Contd..2), H1 2015 274

Pulmonary Fibrosis-Dormant Projects (Contd..3), H1 2015 275

Pulmonary Fibrosis-Discontinued Products, H1 2015 276

List of Figures

Number of Products under Development for Pulmonary Fibrosis, H1 2015 18

Number of Products under Development for Pulmonary Fibrosis-Comparative Analysis, H1 2015 19

Number of Products under Development by Companies, H1 2015 20

Number of Products under Investigation by Universities/Institutes, H1 2015 26

Comparative Analysis by Clinical Stage Development, H1 2015 28

Comparative Analysis by Early Stage Products, H1 2015 29

Assessment by Monotherapy Products, H1 2015 93

Number of Products by Top 10 Targets, H1 2015 95

Number of Products by Stage and Top 10 Targets, H1 2015 95

Number of Products by Top 10 Mechanism of Actions, H1 2015 99

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 99

Number of Products by Top 10 Routes of Administration, H1 2015 102

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 102

Number of Products by Top 10 Molecule Types, H1 2015 104

Number of Products by Stage and Top 10 Molecule Types, H1 2015 104

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AdAlta Pty Ltd.

Aeolus Pharmaceuticals, Inc.

AnaptysBio, Inc.

Angion Biomedica Corp.

Aquinox Pharmaceuticals Inc.

Auspex Pharmaceuticals, Inc.

Biogen Idec Inc.

BiOrion Technologies B.V.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Carolus Therapeutics, Inc.

Celgene Corporation

Chong Kun Dang Pharmaceutical Corp.

Compugen Ltd.

Corridor Pharmaceuticals Inc.

Digna Biotech, S.L.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

FibroGen, Inc.

Five Prime Therapeutics, Inc.

Galectin Therapeutics, Inc.

GenKyoTex S.A.

Gilead Sciences, Inc.

GlaxoSmithKline plc

HanAll Biopharma Co., Ltd.

Histocell S.L.

iBio, Inc.

IMMD Inc.

ImmuneWorks, LLC

IntelGenx Corp.

InterMune, Inc.

Inventiva SAS

Kasiak Research Pvt. Ltd.

Kyorin Pharmaceutical Co., Ltd.

Lanthio Pharma B.V.

Lpath, Inc.

LTT Bio-Pharma Co., Ltd.

MedImmune, LLC

Mesoblast Limited

miRagen Therapeutics, Inc.

Moerae Matrix, Inc.

MSM Protein Technologies, Inc.

NicOx S.A.

Pacific Therapeutics Ltd.

Pharmaxis Limited

Pluristem Therapeutics Inc.

Progenra, Inc.

Promedior, Inc.

ProMetic Life Sciences Inc.

Pulmatrix, Inc.

RestorGenex Corporation

Rhizen Pharmaceuticals SA

Sanofi

Therametrics holding AG

Vectura Group plc

Pulmonary Fibrosis Therapeutic Products under Development, Key Players in Pulmonary Fibrosis Therapeutics, Pulmonary Fibrosis Pipeline Overview, Pulmonary Fibrosis Pipeline, Pulmonary Fibrosis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com